Introduction
The more frequent use of imaging studies of the abdomen, especially ultrasonography (US), has lead to frequent consultation because of the finding of an (often) asymptomatic hepatic lesion. The lesion can be solid or cystic, benign or malignant, or a primary or secondary neoplasm. These patients should be evaluated with thorough clinical history and appropriate diagnostic studies. The most frequent benign solid and cystic lesions of the liver are listed in Table 3 .1.
Hemangioma
The incidence of hemangiomas is approximately 5% in adults and 7% in autopsies, and they are the most frequently identified lesion in the liver. Hemangiomas are more frequent in women and adults. The most usual form are the capillary hemangiomas, typically small, followed by the cavernous hemangiomas, which can reach considerable size and are more likely to cause symptoms. Hemangiomas (Fig. 3.1a ) usually have characteristic features on imaging that allow a confident, non-invasive diagnosis (see Chapter 2). Grossly, these lesions are well delineated, and their macroscopic aspect is easy to recognize by the surgeon (Fig. 3.1b) . The hemangioma sometimes generates a fibrous plane in contact with the liver, facilitating its enucleation.
Symptoms arise typically from compression of adjacent organs or rapid enlargement due to intratumoral bleeding or thrombosis. Rupture with bleeding into the peritoneum is exceedingly rare, but when this occurs, the associated mortality The literature mentions frequently the term "giant" hemangioma with no consensus regarding the size of the lesion. Hemangiomas with a diameter >4 cm are described as giant hemangiomas but do not imply any special therapeutic implications. The mass effect of large hemangiomas 20 cm or larger may produce discomfort, malaise, or obstructive symptoms and may be palpable on physical examination. Clear correlation of the symptoms with the lesion should guide the appropriateness of operative intervention. Laboratory work-up is typically normal, even for large hemangiomas. The KasabachMerritt syndrome, most commonly described in patients with thrombocytopenia and consumption coagulopathy secondary to skin and spleen hemangiomas, may occur rarely with liver hemangiomas. Very few cases have been described, and the treatment is enucleation or liver transplantation.
Imaging studies beginning with US usually make the diagnosis. Fortunately, good quality US and its adequate interpretation is usually sufficient for the diagnosis of hemangioma. Hyperechogenicity with well-defined borders is typical, and if Doppler exam is added, a greater vascular flow is appreciated easily. Typical CT findings suggesting hemangioma include a hypodense lesion in comparison with the surrounding liver parenchyma. After injecting intravenous contrast, the lesion fills irregularly from the periphery reaching the center after a few minutes. The enhanced lesion persists longer than the rest of the liver (Fig. 3.1 ). This finding is typical of hemangioma. The specificity of MRI exceeds that of CT in the diagnosis of hemangioma. Disadvantages of MRI, however, include cost, availability, expertise, and contraindications in persons with pacemakers or metallic prostheses, and it may require sedation in claustrophobic patients. Both methods allow simultaneous evaluation of the remainder of the abdomen as well. MRI offers the advantage of use in patients with allergy to contrast media. Hemangiomas are characteristically hyperintense on the T2-weighted images; after administration of gadolinium, a peripheral filling lesion similar to CT findings is noted. Although hepatic scintigraphy with 99m Tc-labeled red blood cells has diagnostic merit, this study has been supplanted by the previously described 3 Benign Hepatic Neoplasms imaging methods. Selective arteriography of the liver shows a corkscrew aspect of the vessels and a cotton-like filling, both of which are very characteristic. This method is almost never required because of its cost and invasive nature.
Biopsy of lesions suspicious for hemangioma is generally not advised due to the risk of complications and failure to exclude definitively a neoplasm. A biopsy of any focal liver lesion is useful only if it will change the therapeutic plan; otherwise, the lesion should be observed or resected.
For asymptomatic hemangiomas, once a confident diagnosis has been made, the therapeutic approach for the vast majority of these cases is periodic observation. Yearly follow-up of the lesion with US may demonstrate that the lesion does not grow and does not develop changes within the lesion. Complications developing from an asymptomatic lesion during follow-up are very unusual, not predictable, and do not justify resection.
Rarely, one may see a hemangioma that enlarges through the years, for instance, during pregnancy ( Fig. 3.2) .
The indications for resection of hemangioma include symptomatic lesions or patients in whom the diagnosis is uncertain. Patient concerns, performance status, and other medical conditions also impact the decision for operative intervention. Some patients with a large hemangioma have been advised erroneously to undergo extirpation of the hemangioma because of a b symptoms not related to the neoplasm. In a very anxious patient in whom the lesion is easily resectable, the operative risk is relatively low, and if the patient understands the risks, resection may be appropriate. The majority of symptomatic, resected, or complicated hemangiomas are larger than 10 cm. The management of hemangiomas that measure ³ 15 cm is controversial in otherwise asymptomatic patients. It seems reasonable to observe them periodically and carefully, and if there is any evidence of growth or symptomatology, to resect them. Operative resection involves enucleation or formal anatomic resection, depending on the location and relationship to portal branches and hepatic veins. Operative approach, laparotomy, and laparoscopic approaches depend on the location, size, and characteristics of the lesion. Planning the resection will also depend on intra-operative findings. Sometimes a simple enucleation of a hemangioma that "hangs" from the liver will be possible; in other patients, the hemangioma may be a deep lesion that requires a surgeon expert in hepatic resections. Often a fibrous plane exists between the hemangioma and the hepatic tissue that facilitates a safe and easy enucleation. An especially useful tool is the ultrasonic dissector that facilitates enucleation of the hemangioma. Because hemangiomas are benign lesions, it is not necessary to resect margins of healthy liver. Full visualization and mobilization of the liver with early control of the vascular pedicles facilitates the resection. On occasion, a dominant hepatic artery or an arterial branch that feeds preferentially the lesion can be found.
Preemptive transvascular embolization of the hemangioma is not justified based on the low risk of spontaneous hemorrhage but has been very useful in the management of ruptured hemangiomas. It is not uncommon to find neighboring smaller hemangiomas when resecting a large one; however, they require no intervention, because they have an exceedingly small risk of becoming symptomatic. Postoperative complications are rare and are the same as those found in any hepatic resection.
Focal Nodular Hyperplasia (FNH)
FNH was first described in 1958. This lesion believed to be hormone-dependent is much more frequent in young women and has been related to the use of oral contraceptives. FNH can reach considerable size, yet most are asymptomatic and found only incidentally on an imaging procedure for another complaint. When symptoms do appear, they are secondary to its mass effect. Malignant degeneration or hemorrhage has not been described. FNH is a macroscopically well-defined lesion without a capsule arising within otherwise normal hepatic tissue. The lesion appears more pale than normal liver, has prominent vessels on its surface, and presents a somewhat lobulated aspect, with a firm, rubbery consistency ( Fig. 3.3a) . Frequently, a central radial scar consisting of a vascularized fibrous septum is seen characteristically on imaging studies. Histologically, this lesion suggests a regenerative nodule with a predominance of Küpffer cells and biliary duct hyperplasia, thus differentiating FNH histologically from adenomas. Differentiating FNH from adenoma preoperatively on imaging studies, however, may prove challenging. Biliary scintigraphy with radiolabeled sulfur colloid shows a prominent uptake by the abundant Küpffer cells into the FNH, thereby allowing the differentiation from adenoma. Ultrasonography shows an echogenic lesion but only occasionally having the "characteristic" central, vascularized scar. CTandMRIshowa homogeneous,vascularized lesion and, when present, outlining a radial central scar with a "cartwheel" aspect ( Fig. 3.4 ) that differentiates FNH from adenoma; however, smaller lesions usually lack the features. Arteriography is not recommended, but when done will show a well-vascularized lesion and, when present, the central, vascularized scar. Usually one of these techniques will permit a confident diagnosis. On occasion, however, a small lesion (<5 cm) can be seen in a central location. Biopsy is not recommended, because it will usually be inconclusive. In patients without substantive risk factors like cirrhosis or chronic viral infection, follow-up imaging in 3-6 months seems the best approach; if the lesion remains unchanged over time, a benign lesion seems most likely. Growth in size, however, warrants an aggressive approach. For the peripherally located, small lesions, a laparoscopic wedge excision may be the best approach unless FNH is highly suspected, in which case follow-up imaging surveillance seems best. Treatment of known FNH is limited to observational surveillance and discontinuation of oral contraceptives in women. Because there is no worry of malignant degeneration or other complications within the lesion (bleeding, necrosis, abscess, etc.), there is no justification for resection unless there are symptoms related to its mass effect. Under these circumstances, the operative treatment consists of enucleation; there is no need to perform a wedge-type excision or formal anatomic resection of a known FNH. The vast majority of FNHs, however, are resected because of an uncertain diagnosis; in these cases, the resection is performed according to location and with oncologic intent.
Hepatocellular Adenoma
Hepatocellular adenomas (HA) are usually seen in young women and are associated with the use of hormones. These benign neoplasms are well-delineated, solitary, benign neoplasms of a few centimeters in size, yellow-pink in color, soft on palpation, and showing foci of hemorrhagic dots on the transected surface. Certain patient populations are predisposed to developing HA, including patients with galactosemia, type 1 glycogen deposits, Turner's and Klinefelter's syndromes, and most conspicuously, users of oral contraceptives, estrogens, androgens, danazol, clomiphene, and growth hormone. The relationship between HA and oral contraceptives, as well as with pregnancy, is well-described; indeed, patients showing growth of an HA during pregnancy are well-documented, lending strong support to the association of HA and steroid sex hormones. A decrease in the size of the HA has also been described when oral contraceptives are discontinued.
The risk of developing HA in oral contraceptive users depends on the concentration of the estrogen, duration of use (more than 2 years), and the woman's age (>30 years of age). Overall, however, the risk is extremely low and must vary with individual genomic predisposition. Of concern, however, is that there is a greater risk of rupture and bleeding during pregnancy in patients with known HA. In addition, the co-existence of HA and the development of hepatocellular carcinoma has been postulated, although the evidence supporting a definite association is difficult to confirm. Histologically, HAs consist of a homogeneous population of hepatocytes that may contain abundant glycogen; a notable absence of the portal triads and biliary ducts and the presence of thin-walled blood vessels and peliosis are pathognomonic findings. Sometimes it can be very difficult to differentiate well-differentiated hepatocarcinomas from HAs.
Adenomas are usually asymptomatic but on rare occasions may present with rupture and massive bleeding. They are most often detected on imaging studies performed for other, non-specific abdominal symptoms that are difficult to relate to the lesion. Laboratory work-up for abnormalities in liver enzymes, tumor markers, or viral infection should be normal. Imaging studies are crucial for their categorization to differentiate HAs from FNH, hepatocellular carcinoma, or metastases; a scintigraphic study (with 99m Tc colloid sulphur), as described previously in the differential diagnosis with FNH, may be useful. On US, HA appears as an echogenic lesion. On CT, it looks hyperdense prior to giving intravenous contrast and variable in intensity after contrast administration. On MRI, the HA is hyperintense on T1-weighted images, iso-intense or less prominent on T2-weighted images, and with the use of gadolinium, it becomes very prominent. Angiography is indicated rarely but will show a hypervascularized lesion with areas of hemorrhage and tortuous vessels. The diagnosis of HA is made usually by excluding other alternatives more pathognomonic on imaging. Differentiation from hepatocellular carcinoma is most problematic and may require resection to prove. Biopsy of the lesion, as mentioned in the description of FNH, is not indicated, because it is not helpful.
The appropriate treatment of HA is resection when there is risk of rupture, bleeding, or question of the diagnosis. The operative approach, laparotomy or laparoscopy, will depend on the location and characteristics of the lesion. Enucleation, wedge resection, or local ablation is usually sufficient. Although experience with alcohol injection or radiofrequency ablation is limited, these approaches seem reasonable in selected situations. Oral contraceptives must be stopped, and long-term follow-up with ultrasonography is recommended in patients in whom resection is not indicated.
Angiomyolipoma
This rare, benign neoplasm of mesenchymal origin is usually seen in the kidney but also rarely in the liver. Its relationship to tuberous sclerosis is not well-defined but appears to be real. The histologic characteristics consist of a mixture of lipomatous tissue, blood vessels, and smooth muscle in variable proportions. The tumor may be single or multiple and often reaches quite a large size. The pre-operative diagnosis can be difficult, but the MRI finding of a tumor full of fat is useful for diagnosis. Percutaneous biopsy has a poor a b yield and may suggest a sarcoma. The malignant potential of this tumor is not clear. Given the rarity of this neoplasm and its diagnostic difficulty, it seems prudent to recommend resection (Fig. 3.5a, b) .
Inflammatory Pseudotumor of the Liver
This entity was described in the liver in 1953. This lesion presents as a well-defined mass with foci of hemorrhage and necrosis, a chronic inflammatory infiltrate, and proliferation of fibrous elements. Although often treated aggressively by resection, its natural evolution when diagnosed correctly is toward spontaneous regression. The pathogenesis has been attributed to an infectious origin with an intense inflammatory response; others have treated inflammatory pseudotumors with steroids. The diagnosis is based ultimately on the histology, and if suspected highly, a biopsy would preclude resection; however, as with all liver tumors, biopsy is fraught with the possibility of seeding if the tumor is malignant, and this possibility should be kept in mind when considering biopsy. Because of such concerns, resection is the usual approach to these unusual liver tumors.
Other Benign Tumors
There is a variety of other benign neoplasms in the liver, but each has an extremely low incidence, including biliary hamartoma, solitary fibrous tumor, benign mesothelioma, lipoma associated with myolipoma or angiolipoma, mesenchymal hamartoma, mixoma, and teratoma.
Incidentally Discovered Liver Lesions
With the widespread use of state-of-the-art imaging, the recognition of liver lesions has become relatively frequent. These abnormalities on imaging can cause great anxiety in the patient, and the clinician must present an organized, systematic approach to diagnosis and therapy. The first point is to differentiate cystic from solid lesions (see Chapter 2). Once a cystic lesion has been excluded, the next step is to determine whether this solid tumor is benign or malignant, because this may determine either resection versus observation or enucleation versus formal, anatomic resection. The patient's age, history, and clinical background becomes very important. The presence of other hepatic diseases, history of extrahepatic malignancies, neoplasias that could have given rise to a metastasis, alcoholism, trauma, viral infections, particularly hepatitis B or C, and the use of medications, mainly estrogens, contraceptives, or toxic drugs, may prove very important. Laboratory evaluation usually includes hepatic function tests and screening for the existence of markers of past or current hepatitis B or C infection. Tumor markers such as a fetoprotein and embryonic antigen are used selectively, based on the clinical history and characteristics of imaging. Imaging studies usually begin with US, but usually also require CT and/or MRI to make a more definitive diagnosis. Biliary scintigraphy may differentiate adenoma from focal nodular hyperplasia. Selective arteriography is used or indicated only infrequently but may be helpful to detect neovasculature characteristic of hepatocellular carcinoma.
In summary, the most common benign tumors of the liver are cavernous hemangioma, hepato-cellular adenoma (HA), and focal nodular hyperplasia (FNH). Imaging studies usually allow a confident diagnosis of these three benign lesions. When there is question of the diagnosis, resection is usually indicated, because percutaneous liver biopsy risks seeding of the neoplasm if malignant. When the diagnosis is HA, we usually recommend resection, because HA is associated with the risk of bleeding, rupture, or potential malignant degeneration. Hemangiomas and FNH are managed by observation and have a operative indication only if they are symptomatic.
Small lesions (<2 cm) are difficult to characterize with imaging, and if there are no risk factors for neoplasia, we recommend a program of periodic surveillance, particularly if
